Contact Us

U.S. Influenza Vaccines Market– Prevention of Virus through Vaccination Aids in Reducing Burden of the Disease

Influenza is an infection caused by influenza virus and is commonly known as flu. Vaccination for influenza aids in prevention of flu. This vaccine is recommended for children aged 6 months and older. Moreover, according to the World Health Organization (WHO), 2017, influenza virus is transmitted primarily by respiratory secretions or droplets of the infected person. It has an annual global attack rate of 5-10% in adults and 20–30% in children. Influenza vaccines are available with a wide range of options for different age groups such as children aged 6 months and above and adults aged 65 and above. According to the American Public Health Association, 2015, influenza vaccines confer protection with 60–90% efficacy among the recipients, thus increasing the adoption rate of the vaccines.

The U.S. influenza vaccines market was valued at US$ 2.6 billion in 2019 and is expected to witness a CAGR of 16.1% over the forecast period (2019–2027).

Figure 1. U.S. Influenza Vaccines Market Share (%), by Vaccine Type, 2019 and 2027

U.S. Influenza Vaccines  | Coherent Market Insights

Source: Coherent Market Insights (2020)

Rising incidence of pandemic events and increasing awareness, leading to improved pandemic preparedness is expected to boost the market growth.

Rising pandemic events is mainly attributed to genetic diversity of influenza viruses with varying patterns and severity. Risk of the onset of a novel pandemic strain has resulted in rise in research and development for production of efficacious influenza vaccines. Pandemic planning is expected to reduce transmission of pandemic virus, which can eventually decrease hospitalizations and deaths, thus minimizing the social and economic impact of pandemic events. For instance, the Centers for Medicare & Medicaid Services (CMS) provides reimbursement covering 100% of the costs of one seasonal influenza virus vaccinations per influenza season, and it also covers additional seasonal influenza virus vaccinations. Thus, favorable reimbursement is a positive factor to increase adoption rates of influenza vaccines, thus propelling the market growth.

However, shortage of vaccine supply due to genetic assortment of the viral strains is surging the need for updating vaccines each year by the manufacturers. This is a major factor that is expected to restrain the market growth. 

Government initiatives to tackle such events is a major factor that is expected to propel growth of the U.S. influenza vaccine market.

The government agencies in the U.S. are focusing on collaborations, in order to increase the supply of influenza vaccines. For instance, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) the U.S. Department of Health and Human Services Biomedical Advanced Research, and Development Authority (BARDA) are working together for developing new and better influenza vaccines, as a part of inter-agency government effort in the U.S. Moreover, the recommendation from the Advisory Committee on Immunization Practices to receive influenza vaccine, in order to reduce the substantial annual health burden of the disease, is expected to augment growth of the U.S. influenza vaccine market over the forecast period.

Additionally, key players in the market are focusing on strategic mergers and acquisitions to tackle the problem of vaccine shortage. For instance, in August 2017, Sanofi Pasteur acquired Protein Sciences Corporation, thus adding Flublok product to its portfolio, the only U.S. FDA approved recombinant protein-based influenza vaccine. With the acquisition, Sanofi expanded its influenza vaccine portfolio and its presence in the U.S. influenza vaccines market by exploring the non-egg-based manufacturing technologies.

The key players operating in the U.S. influenza vaccines market include Sanofi Pasteur, Seqirus Vaccines Ltd., GlaxoSmithKline Plc., and Medimmune.

Influenza is commonly referred as flu, a contagious respiratory illness that is caused by influenza virus. The virus can cause mild to severe illness, resulting in serious outcomes such as hospitalization or death. Geriatric population, pregnant women, and people with chronic health conditions are at high risk of serious flu complications. Influenza virus is responsible for seasonal epidemic events and are classified into two types of influenza virus, including A and B. The influenza vaccines market is expected to gain significant traction over the forecast period, as number of manufacturers are increasing the production capacity of vaccines for use in the U.S. market for the 2017–2018 influenza season using the innovative technologies such as egg-based, cell-based, and recombinant technologies.

Market Dynamics

The major factors driving growth of the U.S. influenza vaccines market include rapid advancements in technology for development of new vaccines such as recombinant and cell-based technologies, resulting in increasing production of the vaccines. Influenza flu vaccination have the potential to reduce the risk of flu-associated hospitalization among children and adults. For instance, according to the Centers for Disease Control and Prevention, 2015, flu vaccinations prevented around 1.9 million flu illnesses, 966,000 flu-associated medical visits, and around 67,000 flu-associated hospitalizations, representing 6.5% lowering of disease burden in the U.S. Moreover, the collaborative efforts of various government bodies such as U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) with the private sector has led to development of improved influenza vaccine technologies in the U.S. This in turn, has improved influenza pandemic preparedness in the country. Furthermore, National Institute of Allergy and Infectious Disease (NIAID) supports research efforts to improve seasonal flu vaccine strain selection and vaccine effectiveness. However, high cost of manufacturing and complexity of the production process of vaccine due to inherent variability of the viral strains are the major factors that are expected to hinder growth of the U.S. influenza vaccines market over the forecast period.

Key features of the study:

  • This report provides in-depth analysis of U.S. influenza vaccines market and provides market size (US$ Billion) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2019–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the U.S. influenza vaccines market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Sanofi Pasteur, Seqirus Vaccines Ltd., GlaxoSmithKline Plc., and Medimmune
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The U.S. influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. influenza vaccines market

Detailed Segmentation:

  • U.S. Influenza Vaccines Market, By Vaccine Type:
    • Trivalent Vaccines
    • Quadrivalent Vaccines
  • U.S. Influenza Vaccines Market, By Virus Type:
    • Influenza Virus Type A
    • Influenza Virus Type B
  • U.S. Influenza Vaccines Market, By Age Group:
    • Pediatrics
    • Adults
  • Company Profiles
    • Sanofi Pasteur*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Seqirus Vaccines Ltd.
    • GlaxoSmithKline Plc.
    • Medimmune

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Vaccine Type
      • Market Snippet, By Virus Type
      • Market Snippet, By Age Group
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • Epidemiology
    • PEST Analysis
    • Key Highlights
    • Recommendations for Nasal Spray Vaccines
    • Influenza Vaccines Production Technologies
    • Influenza Vaccines Approved in U.S., 2017-18 Influenza Season
    • Influenza Vaccine Price List
    • Supply Capacity of Major Manufacturers
  4. U.S. Influenza Vaccines Market, By Vaccine Type, 2016–2027, (US$ Billion)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Trivalent Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
    • Quadrivalent Vaccines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
  5. U.S. Influenza Vaccines Market, By Virus Type, 2016–2027, (US$ Billion)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Influenza Virus Type A
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
    • Influenza Virus Type B
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
  6. U.S. Influenza Vaccines Market, By Age Group, 2016–2027, (US$ Billion)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Pediatrics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
    • Adults
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Billion)
  7. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis (3x3 Matrix)
    • Company Profiles
      • Sanofi Pasteur*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Seqirus Vaccines Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • GlaxoSmithKline Plc
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Medimmune
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Analyst Views
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 20 market data tables and 15 figures on "U.S. Influenza Vaccines Market - forecast to 2027”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Data Triangulation Methodology | Coherent Market Insights

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Market Analysis | Coherent Market Insights

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users